NASDAQ:BYSI BeyondSpring Q4 2025 Earnings Results & Report $0.61 +0.00 (+0.21%) As of 09:56 AM Eastern This is a fair market value price provided by Massive. Learn more. BeyondSpring beat analyst earnings expectations in its Q4 2025 results, released March 25, 2026. The company reported EPS of -$0.05 versus the -$0.54 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 25, 2026TimeBefore Market Opens BeyondSpring EPS ResultsActual EPS-$0.05Consensus EPS -$0.54Beat/MissBeat by +$0.49One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersBeyondSpring Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsBeyondSpring's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K) BeyondSpring Q4 2025 Earnings FAQ Did BeyondSpring beat earnings estimates for Q4 2025? BeyondSpring (NASDAQ:BYSI) reported earnings of -$0.05 per share for Q4 2025, beating the consensus estimate of -$0.54. The report was announced on Wednesday, March 25, 2026. When is BeyondSpring's next earnings date? BeyondSpring's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for BeyondSpring on the company's earnings history page. BeyondSpring Earnings HeadlinesBeyondSpring Shareholders Ratify 2026 Auditor AppointmentOctober 13 at 5:10 PM | tipranks.comHead to Head Analysis: BeyondSpring (NASDAQ:BYSI) and Vertex Pharmaceuticals (NASDAQ:VRTX)October 6, 2026 | americanbankingnews.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 14 at 1:00 AM | Paradigm Press (Ad)BeyondSpring Wins FDA Fast Track for Plinabulin Lung Cancer ProgramOctober 5, 2026 | americanbankingnews.comBeyondSpring Faces Nasdaq Listing Compliance RiskOctober 2, 2026 | tipranks.comBeyondSpring Inc. Announces FDA Fast Track Designation For Plinabulin And Docetaxel In Post-ICI Non-Squamous NSCLCSeptember 29, 2026 | marketscreener.comMSee More BeyondSpring Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeyondSpring? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeyondSpring and other key companies, straight to your email. Email Address About BeyondSpringBeyondSpring (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research centers on treatments designed to improve outcomes for patients receiving chemotherapy and to enhance the body’s immune response against tumors. BeyondSpring’s lead product candidate is plinabulin, also known as BPI-2358 or NPI-2358. Plinabulin is a small-molecule therapy being studied for the prevention of chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells, as well as for possible use in oncology treatment combinations. The company has also investigated plinabulin in combination with other cancer therapies and across multiple tumor types. Founded in 2010, BeyondSpring has conducted clinical development activities in the United States and China, among other international markets. The company was led by co-founder Lan Huang, who has served as chief executive officer and chairman. BeyondSpring’s programs have progressed through clinical testing and regulatory review, although the development and approval status of individual candidates may change as the company receives additional regulatory and clinical feedback.View BeyondSpring ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
